Correction: Beylerli et al. MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas. Int. J. Mol. Sci. 2020, 21, 7287
Ozal Beylerli, Narasimha M. Beeraka, Ilgiz Gareev, Valentin Pavlov, Guang Yang, Yanchao Liang, Gjumrakch Aliev
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPituitary Gland Disorders and Treatments · Cancer, Hypoxia, and Metabolism · PI3K/AKT/mTOR signaling in cancer
In the original publication [1], the following three references, [26,74,76], should be replaced with new references. References [26] and [74] were replaced because the articles were retracted, and reference [76] was replaced because of a citation error. With this correction, the order of some references, the contents of Table 1, and the third paragraph of Section 4 in the article have also been modified accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The corrected references that replaced references [26], [74], and [76] are as follows:
- 26. Zhu, D.; Xiao, Z.; Wang, Z.; Hu, B.; Duan, C.; Zhu, Z. MEG3/MIR-376B-3P/HMGA2 axis is involved in pituitary tumor invasiveness. J. Neurosurg. 2020, 134, 499–511. https://doi.org/10.3171/2019.10.JNS191959.
-
- Shahrzad, J.; Monsalves, E.; Tateno, T.; Zadeh, G. Role of mTOR inhibitors in growth hormone-producing pituitary adenomas harboring different FGFR4 genotypes. Endocrinology 2016, 157, 3577–3587.
-
- Bin, H.; Mao, Z.; Du, Q.; Jiang, X.; Wang, Z.; Xiao, Z.; Zhu, D.; Wang, X.; Zhu, Y.; Wang, H. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma. Brain Res. Bull. 2019, 149, 21–31.
The corrected version of Table 1 is as follows:
The correct contents of the third paragraph of Section 4 are as follows:
mTOR is a serine–threonine specificity protein kinase that controls cell growth and metabolism in response to various substances, growth factors, and cell stress [71]. As a central regulator of cell growth, mTOR plays a key role in the development and aging of cells and is involved in the pathogenesis of cardiovascular diseases, endocrine diseases, metabolic disorders, and tumors [72]. Antiproliferative responses to mTOR inhibition have been reported in studies with aggressive PA in vitro and in vivo [73,74]. mTOR mRNA expressions significantly modulated in invasive pituitary adenoma tissues were compared with those in noninvasive pituitary adenoma tissues [73,74].
The reference list from the paper itself. Each links out to its DOI / PubMed record.